^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoScreen Plus®

    Company:
    Burning Rock Biotech
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    OncoScreen Plus® is a targeted NGS panel that covers 520 tumor related genes. It does comprehensive screening of immune molecular markers TMB, MSI, DDR pathway genes, other positive and negative prediction and hyperprogression factors and it covers all targeted therapy related genes comprehensively guide immune and targeted therapy.
    Cancer:
    Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Kidney Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Retinoblastoma, Skin Cancer, Solid Tumor, Thyroid Gland Carcinoma
    Gene:
    MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    05/07/22
    ST
    -
    CE